1. Academic Validation
  2. Pharmacokinetics of neomycin sulfate after intravenous and oral administrations in swine

Pharmacokinetics of neomycin sulfate after intravenous and oral administrations in swine

  • J Vet Pharmacol Ther. 2021 Sep;44(5):850-853. doi: 10.1111/jvp.12981.
Yu Liu 1 2 Yuxin Yang 1 2 Yuying Cao 1 2 Jicheng Qiu 1 2 Jingyuan Kong 1 2 Lu Zhang 1 2 Yanying Guo 1 2 Mingchuan Zhang 3 Xingyuan Cao 1 2 4 Suxia Zhang 1 2 4
Affiliations

Affiliations

  • 1 Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing, China.
  • 2 Laboratory of Quality & Safety Risk Assessment for Animal Products on Chemical Hazards (Beijing), Ministry of Agriculture and Rural affairs of the People's Republic of China, Beijing, China.
  • 3 Beijing YuanDa Spark Medicine Technology Co., Ltd, Beijing, China.
  • 4 Key Laboratory of Detection for Veterinary Drug Residues and Illegal Additives, Ministry of Agriculture and Rural affairs of the People's Republic of China, Beijing, China.
Abstract

The Aminoglycoside antibiotic neomycin, which is used to treat external or internal Bacterial infections, is primarily administered in veterinary medicine as a sulfate salt. However, no information is available on the pharmacokinetic characteristics and absolute availability of neomycin sulfate after intravenous (i.v.) and oral (p.o.) administrations in swine. Here, these parameters were studied in swine after i.v. and p.o. doses of single 15 mg/kg body weight doses. The blood samples were assessed using ultra-high-performance liquid chromatography-tandem mass/mass spectrometry (UPLC-MS/MS) and pharmacokinetic parameters were analyzed using a non-compartmental model. In swine, after the p.o. administration, the elimination half-life, mean residue time from t0 to the last collection point, mean maximum concentration, mean time to reach maximum concentration and area under concentration-time curve from t0 to the last collection point values were 12.43 ± 7.63 h, 10.25 ± 4.32 h, 0.11 ± 0.07 μg/ml, 1.92 ± 0.97 h and 1.23 ± 0.78 μg·h/ml, respectively, whereas after the i.v. administration, the values were 5.87 ± 1.12 h, 6.07 ± 0.49 h, 15.80 ± 1.32 μg/ml, 0.30 ± 0.38 h and 76.14 ± 3.52 μg·h/ml, respectively. The absolute bioavailability of neomycin sulfate B was 4.84%±0.03.

Keywords

bioavailability; intravenous administration; neomycin sulfate; oral administration; pharmacokinetics.

Figures
Products